{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:45:10Z","timestamp":1790264710362,"version":"4.1.0"},"reference-count":144,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS462"],"award-info":[{"award-number":["DS462"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR)-T cells (CART) remain one of the most advanced and promising forms of adoptive T-cell immunotherapy. CART represent autologous, genetically engineered T lymphocytes expressing CAR, i.e. fusion proteins that combine components and features of T cells as well as antibodies providing their more effective and direct anti-tumour effect. The technology of CART construction is highly advanced in vitro and every element of their structure influence their mechanism of action in vivo. Patients with haematological malignancies are faced with the possibility of disease relapse after the implementation of conventional chemo-immunotherapy. Since the most preferable result of therapy is a partial or complete remission, cancer treatment regimens are constantly being improved and customized to individual patients. This individualization could be ensured by CART therapy. This paper characterized CART strategy in details in terms of their structure, generations, mechanism of action and published the results of clinical trials in haematological malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and multiple myeloma.<\/jats:p>","DOI":"10.1007\/s00005-020-00599-x","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T06:03:26Z","timestamp":1604642606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Application of CAR-T Cells in Haematological Malignancies"],"prefix":"10.2478","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8758-6539","authenticated-orcid":false,"given":"Katarzyna","family":"Skorka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Ostapinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Malesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"599_CR1","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Gordon LI, Palomba ML et al (2018a) Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J Clin Oncol 36:7505\u20137505. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.7505","journal-title":"J Clin Oncol"},{"key":"599_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2018.36.5_suppl.120","volume":"36","author":"JS Abramson","year":"2018","unstructured":"Abramson JS, Siddiqi T, Palomba ML et al (2018b) High durable CR rates and preliminary safety profile for JCAR017 in R\/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol 36:120\u2013120. https:\/\/doi.org\/10.1200\/JCO.2018.36.5_suppl.120","journal-title":"J Clin Oncol"},{"key":"599_CR3","unstructured":"Abramson JS, Palomba LM, Gordon LI et al (2020) Safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL). Transplantation and cellular therapy meetings, February 19\u201323, 2020, Orlando, Florida"},{"key":"599_CR4","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I et al (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128:1688\u20131700. https:\/\/doi.org\/10.1182\/blood-2016-04-711903","journal-title":"Blood"},{"key":"599_CR5","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","volume":"184","author":"S Bagley","year":"2010","unstructured":"Bagley S, Hawkins RE, Gilham DE et al (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex. J Immunol 184:6938\u20136949. https:\/\/doi.org\/10.4049\/jimmunol.0901766","journal-title":"J Immunol"},{"key":"599_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL et al (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20:1283. https:\/\/doi.org\/10.3390\/ijms20061283","journal-title":"Int J Mol Sci"},{"key":"599_CR7","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ et al (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3:16011. https:\/\/doi.org\/10.1038\/mto.2016.11","journal-title":"Mol Ther Oncolytics"},{"key":"599_CR8","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Rivi\u00e8re I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817\u20134828. https:\/\/doi.org\/10.1182\/blood-2011-04-348540","journal-title":"Blood"},{"key":"599_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/156652310791111001","volume":"10","author":"J Bridgeman","year":"2010","unstructured":"Bridgeman J, Hawkins R, Therapy AH (2010) Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10:77\u201390","journal-title":"Curr Gene Ther"},{"key":"599_CR10","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.v96.5.1999.h8001999_1999_2001","volume":"96","author":"T Brocker","year":"2000","unstructured":"Brocker T (2000) Chimeric Fv-\u03b6 or Fv-\u03b5 receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96:1999\u20132001. https:\/\/doi.org\/10.1182\/blood.v96.5.1999.h8001999_1999_2001","journal-title":"Blood"},{"key":"599_CR11","doi-asserted-by":"publisher","first-page":"16028","DOI":"10.1038\/mto.2016.28","volume":"3","author":"CE Brown","year":"2016","unstructured":"Brown CE, Adusumilli PS (2016) Next frontiers in CAR T-cell therapy. Mol Ther Oncolytics 3:16028. https:\/\/doi.org\/10.1038\/mto.2016.28","journal-title":"Mol Ther Oncolytics"},{"key":"599_CR12","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD et al (2018) T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 36:2267\u20132280. https:\/\/doi.org\/10.1200\/JCO.2018.77.8084","journal-title":"J Clin Oncol"},{"key":"599_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00262-014-1641-9","volume":"64","author":"M Casucci","year":"2015","unstructured":"Casucci M, Hawkins RE, Dotti G et al (2015) Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 64:123\u2013130. https:\/\/doi.org\/10.1007\/s00262-014-1641-9","journal-title":"Cancer Immunol Immunother"},{"key":"599_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA (2019) CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol 10:1\u201320. https:\/\/doi.org\/10.1177\/2040620719841581","journal-title":"Ther Adv Hematol"},{"key":"599_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15:1145\u20131154. https:\/\/doi.org\/10.1517\/14712598.2015.1046430","journal-title":"Expert Opin Biol Ther"},{"key":"599_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acg2.84","volume":"3","author":"M Chmielewski","year":"2020","unstructured":"Chmielewski M, Abken H (2020) TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Ther 3:1\u20139. https:\/\/doi.org\/10.1002\/acg2.84","journal-title":"Adv Cell Gene Ther"},{"key":"599_CR17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA et al (2019) B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Investig 129:2210\u20132221. https:\/\/doi.org\/10.1172\/JCI126397","journal-title":"J Clin Investig"},{"key":"599_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1126\/scitranslmed.3008226.Efficacy","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy. Sci Transl Med 6:224\u2013225. https:\/\/doi.org\/10.1126\/scitranslmed.3008226.Efficacy","journal-title":"Sci Transl Med"},{"key":"599_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B et al (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107\u2013126. https:\/\/doi.org\/10.1111\/imr.12131","journal-title":"Immunol Rev"},{"key":"599_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/jcm8020200","volume":"8","author":"P Dreger","year":"2019","unstructured":"Dreger P, Schubert M-L, M\u00fcller-Tidow C et al (2019) Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML). J Clin Med 8:200. https:\/\/doi.org\/10.3390\/jcm8020200","journal-title":"J Clin Med"},{"key":"599_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01717","volume":"9","author":"R Elahi","year":"2018","unstructured":"Elahi R, Khosh E, Tahmasebi S et al (2018) Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol 9:1\u201318. https:\/\/doi.org\/10.3389\/fimmu.2018.01717","journal-title":"Front Immunol"},{"key":"599_CR22","unstructured":"FDA, CBER (2017) October 18, 2017 summary basis for regulatory action\u2014YESCARTA"},{"key":"599_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth KA, Riley JL, Harris MH et al (2002) The CD28 signaling pathway regulates glucose metabolism of metabolism in response to changes in cellular condi- tions. However, it has recently been shown that signals from cell surface receptors are required to control the ability of resting cells to tak. Immunity 16:769\u2013777. https:\/\/doi.org\/10.1016\/S1074-7613(02)00323-0","journal-title":"Immunity"},{"key":"599_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N (2017) Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol 30:336\u2013340. https:\/\/doi.org\/10.1016\/j.beha.2017.09.002","journal-title":"Best Pract Res Clin Haematol"},{"key":"599_CR25","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","volume":"3","author":"J Garcia Borrega","year":"2019","unstructured":"Garcia Borrega J, G\u00f6del P, R\u00fcger MA et al (2019) In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere 3:e191. https:\/\/doi.org\/10.1097\/HS9.0000000000000191","journal-title":"HemaSphere"},{"key":"599_CR26","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322\u20133331. https:\/\/doi.org\/10.1182\/blood-2017-02-769208","journal-title":"Blood"},{"key":"599_CR27","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/nejmoa1504542","volume":"373","author":"AL Garfall","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang WT et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373:1040\u20131047. https:\/\/doi.org\/10.1056\/nejmoa1504542","journal-title":"N Engl J Med"},{"key":"599_CR28","doi-asserted-by":"publisher","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","volume":"3","author":"AL Garfall","year":"2018","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT et al (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:e120505. https:\/\/doi.org\/10.1172\/jci.insight.120505","journal-title":"JCI Insight"},{"key":"599_CR29","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","volume":"26","author":"MB Geyer","year":"2018","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B et al (2018) Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther 26:1896\u20131905. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.018","journal-title":"Mol Ther"},{"key":"599_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, Van Der Stegen SJC, Eyquem J et al (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat Med 24:731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nat Med"},{"key":"599_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.molmed.2012.04.009","volume":"18","author":"DE Gilham","year":"2012","unstructured":"Gilham DE, Debets R, Pule M et al (2012) CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18:377\u2013384. https:\/\/doi.org\/10.1016\/j.molmed.2012.04.009","journal-title":"Trends Mol Med"},{"key":"599_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","volume":"6","author":"W Glienke","year":"2015","unstructured":"Glienke W, Esser R, Priesner C et al (2015) Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 6:21. https:\/\/doi.org\/10.3389\/fphar.2015.00021","journal-title":"Front Pharmacol"},{"key":"599_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","volume":"120","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Cremer M, Schmitt M et al (2018) Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer 120:38\u201344. https:\/\/doi.org\/10.1038\/s41416-018-0346-9","journal-title":"Br J Cancer"},{"key":"599_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biot.201700097","volume":"13","author":"D Gomes-Silva","year":"2018","unstructured":"Gomes-Silva D, Ramos CA (2018) Cancer immunotherapy using CAR-T cells: from the research bench to the assembly line. Biotechnol J 13:1\u20138. https:\/\/doi.org\/10.1002\/biot.201700097","journal-title":"Biotechnol J"},{"key":"599_CR35","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024\u201310028. https:\/\/doi.org\/10.1073\/pnas.86.24.10024","journal-title":"Proc Natl Acad Sci USA"},{"key":"599_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/nejmoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Wright JF, Rheingold SR et al (2013) Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509\u20131518. https:\/\/doi.org\/10.1056\/nejmoa1215134","journal-title":"N Engl J Med"},{"key":"599_CR37","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"SA Grupp","year":"2015","unstructured":"Grupp SA, Zheng Z, Porter DL et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415","journal-title":"Sci Transl Med"},{"key":"599_CR38","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan S, Chen X, Madar A et al (2014) ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells. Blood 124:1070\u20131080. https:\/\/doi.org\/10.1182\/blood-2013-10-535245","journal-title":"Blood"},{"key":"599_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","volume":"2","author":"B Guo","year":"2016","unstructured":"Guo B, Chen M, Han Q et al (2016) CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother 2:28\u201335. https:\/\/doi.org\/10.1016\/j.jocit.2014.11.001","journal-title":"J Cell Immunother"},{"key":"599_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jcyt.2019.01.003","volume":"21","author":"RP Harrison","year":"2019","unstructured":"Harrison RP, Zylberberg E, Ellison S et al (2019) Chimeric antigen receptor\u2013T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy 21:224\u2013233. https:\/\/doi.org\/10.1016\/j.jcyt.2019.01.003","journal-title":"Cytotherapy"},{"key":"599_CR41","first-page":"20","volume":"17","author":"AF Herrera","year":"2019","unstructured":"Herrera AF (2019) Highlights in lymphoma from the 60th American Society of Hematology annual meeting: commentary. Clin Adv Hematol Oncol 17:20\u201323","journal-title":"Clin Adv Hematol Oncol"},{"key":"599_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S et al (2017) The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess 21:1\u2013204. https:\/\/doi.org\/10.3310\/hta21070","journal-title":"Health Technol Assess"},{"key":"599_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cancers11020191","volume":"11","author":"B Heyman","year":"2019","unstructured":"Heyman B, Yang Y (2019) Chimeric antigen receptor T cell therapy for solid tumors: current status, obstacles and future strategies. Cancers 11:191. https:\/\/doi.org\/10.3390\/cancers11020191","journal-title":"Cancers"},{"key":"599_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy. Blood 131:121\u2013130. https:\/\/doi.org\/10.1182\/blood-2017-07-793760","journal-title":"Blood"},{"key":"599_CR45","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","volume":"167","author":"A Hombach","year":"2001","unstructured":"Hombach A, Wieczarkowiecz A, Marquardt T et al (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule. J Immunol 167:6123\u20136131. https:\/\/doi.org\/10.4049\/jimmunol.167.11.6123","journal-title":"J Immunol"},{"key":"599_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M et al (2012) OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 1:458\u2013466. https:\/\/doi.org\/10.4161\/onci.19855","journal-title":"Oncoimmunology"},{"key":"599_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-012-0145-y.CARs","author":"C Hosing","year":"2014","unstructured":"Hosing C, Keabriaei P, Wierda W et al (2014) CARs in chronic lymphocytic leukemia\u2014ready to drive. Curr Hematol Malig Rep. https:\/\/doi.org\/10.1007\/s11899-012-0145-y.CARs","journal-title":"Curr Hematol Malig Rep"},{"key":"599_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1631\/jzus.B1900351","volume":"21","author":"H Huang","year":"2020","unstructured":"Huang H, Wu H, Hu Y (2020) Current advances in chimeric antigen receptor T-cell therapy for refractory\/relapsed multiple myeloma. J Zhejiang Univ B 21:29\u201341. https:\/\/doi.org\/10.1631\/jzus.B1900351","journal-title":"J Zhejiang Univ B"},{"key":"599_CR49","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet 381:1943\u20131955. https:\/\/doi.org\/10.1016\/S0140-6736(12)62187-4","journal-title":"Lancet"},{"key":"599_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00267","volume":"8","author":"M Irving","year":"2017","unstructured":"Irving M, de Silly RV, Scholten K et al (2017) Engineering chimeric antigen receptor T-cells for racing in solid tumors: don\u2019t forget the fuel. Front Immunol 8:1\u201319. https:\/\/doi.org\/10.3389\/fimmu.2017.00267","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"599_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","volume":"132","author":"CA Jacobson","year":"2018","unstructured":"Jacobson CA, Hunter B, Armand P et al (2018) Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood 132(Suppl 1):92. https:\/\/doi.org\/10.1182\/blood-2018-99-117199","journal-title":"Blood"},{"key":"599_CR52","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ajh.25274","volume":"93","author":"E Jacoby","year":"2018","unstructured":"Jacoby E, Bielorai B, Avigdor A et al (2018) Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol 93:1485\u20131492. https:\/\/doi.org\/10.1002\/ajh.25274","journal-title":"Am J Hematol"},{"key":"599_CR53","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ et al (2010) Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biol Blood Marrow Transplant 16:1245\u20131256","journal-title":"Biol Blood Marrow Transplant"},{"key":"599_CR54","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU et al (2018) CAR T cell immunotherapy for human cancer. Science 359:1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711","journal-title":"Science"},{"key":"599_CR55","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T et al (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35:1803\u20131813. https:\/\/doi.org\/10.1200\/JCO.2016.71.3024","journal-title":"J Clin Oncol"},{"key":"599_CR56","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66:10995\u201311004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0160","journal-title":"Cancer Res"},{"key":"599_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","volume":"8","author":"G Kueberuwa","year":"2018","unstructured":"Kueberuwa G, Kalaitsidou M, Cheadle E et al (2018) CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics 8:41\u201351. https:\/\/doi.org\/10.1016\/j.omto.2017.12.003","journal-title":"Mol Ther Oncolytics"},{"key":"599_CR58","unstructured":"Kymriah (2018) Summary Basis for Regulatory Action. April 13, 2018"},{"key":"599_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL (2018) Programming CAR-T cells to kill cancer. Nat Biomed Eng 2:377\u2013391. https:\/\/doi.org\/10.1038\/s41551-018-0235-9","journal-title":"Nat Biomed Eng"},{"key":"599_CR60","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","volume":"20","author":"TW Laetsch","year":"2019","unstructured":"Laetsch TW, Myers GD, Baruchel A et al (2019) Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol 20:1710\u20131718. https:\/\/doi.org\/10.1016\/S1470-2045(19)30493-0","journal-title":"Lancet Oncol"},{"key":"599_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12272-019-01136-x","volume":"42","author":"YH Lee","year":"2019","unstructured":"Lee YH, Kim CH (2019) Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch Pharmacol Res 42:607\u2013619. https:\/\/doi.org\/10.1007\/s12272-019-01136-x","journal-title":"Arch Pharmacol Res"},{"key":"599_CR61","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3","journal-title":"Lancet"},{"key":"599_CR63","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K et al (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006","journal-title":"Mol Ther Methods Clin Dev"},{"key":"599_CR64","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"D Li","year":"2017","unstructured":"Li D, Harju-Baker S, Chen X et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"599_CR65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"599_CR67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","volume":"53","author":"Y Liu","year":"2017","unstructured":"Liu Y, Chen X, Han W et al (2017) Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today 53:597. https:\/\/doi.org\/10.1358\/dot.2017.53.11.2725754","journal-title":"Drugs Today"},{"key":"599_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382:545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"key":"599_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"599_CR69","doi-asserted-by":"publisher","first-page":"a002485","DOI":"10.1101\/cshperspect.a002485","volume":"2","author":"PE Love","year":"2010","unstructured":"Love PE, Hayes SM (2010) ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb Perspect Biol 2:a002485\u2013a002485. https:\/\/doi.org\/10.1101\/cshperspect.a002485","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"599_CR70","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.CD-17-1084","volume":"7","author":"CL Mackall","year":"2017","unstructured":"Mackall CL, Miklos DB (2017) CNS endothelial cell activation emerges as a driver of CAR T cell\u2013associated neurotoxicity. Cancer Discov 7:1371\u20131373. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1084","journal-title":"Cancer Discov"},{"key":"599_CR71","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody S, Htut M, Lee KP et al (2018) JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE). Blood 132:957\u2013957. https:\/\/doi.org\/10.1182\/blood-2018-99-113548","journal-title":"Blood"},{"key":"599_CR72","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/cas.13239","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108:1109\u20131118. https:\/\/doi.org\/10.1111\/cas.13239","journal-title":"Cancer Sci"},{"key":"599_CR73","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"key":"599_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01071-7","author":"M Mata","year":"2019","unstructured":"Mata M, Gottschalk S (2019) Engineering for success: approaches to improve chimeric antigen receptor T cell therapy for solid tumors. Drugs. https:\/\/doi.org\/10.1007\/s40265-019-01071-7","journal-title":"Drugs"},{"key":"599_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT et al (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20:119\u2013122. https:\/\/doi.org\/10.1097\/PPO.0000000000000035","journal-title":"Cancer J"},{"key":"599_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"599_CR77","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"AD McLellan","year":"2019","unstructured":"McLellan AD, Ali Hosseini Rad SM (2019) Chimeric antigen receptor T cell persistence and memory cell formation. Immunol Cell Biol 97:664\u2013674. https:\/\/doi.org\/10.1111\/imcb.12254","journal-title":"Immunol Cell Biol"},{"key":"599_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2040620714550773","volume":"5","author":"P Mewawalla","year":"2014","unstructured":"Mewawalla P, Nathan S (2014) Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol 5:139\u2013152. https:\/\/doi.org\/10.1177\/2040620714550773","journal-title":"Ther Adv Hematol"},{"key":"599_CR79","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE (2017) Multiple myeloma: diagnosis and treatment. Am Fam Physician 95:373\u2013383","journal-title":"Am Fam Physician"},{"key":"599_CR80","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/02648725.2018.1430465","volume":"33","author":"N Muhammad","year":"2017","unstructured":"Muhammad N, Mao Q, Xia H (2017) CAR T-cells for cancer therapy. Biotechnol Genet Eng Rev 33:190\u2013226. https:\/\/doi.org\/10.1080\/02648725.2018.1430465","journal-title":"Biotechnol Genet Eng Rev"},{"key":"599_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1188\/20.CJON.456","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC et al (2019) Cytokine release syndrome: current perspectives. Immunotargets Ther 8:43\u201352. https:\/\/doi.org\/10.1188\/20.CJON.456","journal-title":"Immunotargets Ther"},{"issue":"Suppl 1","key":"599_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil LJ, Jain MD, Spiegel JY et al (2018) Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience. Blood 132(Suppl 1):91. https:\/\/doi.org\/10.1182\/blood-2018-99-114152","journal-title":"Blood"},{"key":"599_CR83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS (2019) Managing the toxicities of CAR T-cell therapy. Hematol Oncol 37:48\u201352. https:\/\/doi.org\/10.1002\/hon.2595","journal-title":"Hematol Oncol"},{"key":"599_CR84","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen K, Devidas M, Cheng SC et al (2008) Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia 22:2142\u20132150. https:\/\/doi.org\/10.1038\/leu.2008.251","journal-title":"Leukemia"},{"key":"599_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a015511","volume":"3","author":"E Page","year":"2013","unstructured":"Page E, Kwun J, Oh B et al (2013) Lymphodepletional strategies in transplantation. Cold Spring Harb Perspect Med 3:1\u201316. https:\/\/doi.org\/10.1101\/cshperspect.a015511","journal-title":"Cold Spring Harb Perspect Med"},{"key":"599_CR86","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"key":"599_CR87","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/imt.14.44","volume":"6","author":"JM Patel","year":"2014","unstructured":"Patel JM, Dale GA, Vartabedian VF et al (2014) Cancer CARtography: charting out a new approach to cancer immunotherapy. Immunotherapy 6:675\u2013678. https:\/\/doi.org\/10.2217\/imt.14.44","journal-title":"Immunotherapy"},{"key":"599_CR88","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","volume":"91","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ (2016) Adult acute lymphoblastic leukemia. Mayo Clin Proc 91:1645\u20131666. https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.010","journal-title":"Mayo Clin Proc"},{"key":"599_CR89","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG et al (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133\u20134141. https:\/\/doi.org\/10.1182\/blood-2011-12-400044","journal-title":"Blood"},{"key":"599_CR90","unstructured":"Pegram HJ, Purdon TJ, Van Leeuwen JL et al (2016) IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. 29:415\u2013422. https:\/\/doi.org\/10.1038\/leu.2014.215.IL-12-secreting"},{"key":"599_CR91","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fonc.2019.00069","volume":"9","author":"CT Petersen","year":"2019","unstructured":"Petersen CT, Krenciute G (2019) Next generation CAR T cells for the immunotherapy of high-grade glioma. Front Oncol 9:69. https:\/\/doi.org\/10.3389\/fonc.2019.00069","journal-title":"Front Oncol"},{"key":"599_CR92","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-09-0572","volume":"15","author":"AG Polson","year":"2009","unstructured":"Polson AG, Sliwkowski MX (2009) Toward an effective targeted chemotherapy for multiple myeloma. Clin Cancer Res 15:3906\u20133907. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0572","journal-title":"Clin Cancer Res"},{"key":"599_CR93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa1103849","journal-title":"N Engl J Med"},{"key":"599_CR94","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139. https:\/\/doi.org\/10.1126\/scitranslmed.aac5415","journal-title":"Sci Transl Med"},{"key":"599_CR95","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"599_CR96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV (2019) Multiple myeloma: Every year a new standard? Hematol Oncol 37:62\u201365. https:\/\/doi.org\/10.1002\/hon.2586","journal-title":"Hematol Oncol"},{"key":"599_CR97","doi-asserted-by":"publisher","first-page":"eaap9777","DOI":"10.1126\/scisignal.aap9777","volume":"12","author":"MC Ramello","year":"2019","unstructured":"Ramello MC, Benza\u00efd I, Kuenzi BM et al (2019) An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal 12:eaap9777. https:\/\/doi.org\/10.1126\/scisignal.aap9777","journal-title":"Sci Signal"},{"key":"599_CR98","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","volume":"20","author":"CA Ramos","year":"2014","unstructured":"Ramos CA, Savoldo B, Dotti G (2014) CD19-CAR trials. Cancer J 20:112\u2013118","journal-title":"Cancer J"},{"key":"599_CR99","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474:449\u2013461. https:\/\/doi.org\/10.1007\/s00428-018-2484-0","journal-title":"Virchows Arch"},{"key":"599_CR100","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","volume":"94","author":"J Rovira","year":"2015","unstructured":"Rovira J, Valera A, Colomo L et al (2015) Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol 94:803\u2013812. https:\/\/doi.org\/10.1007\/s00277-014-2271-1","journal-title":"Ann Hematol"},{"key":"599_CR101","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388\u2013398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548","journal-title":"Cancer Discov"},{"key":"599_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ et al (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11:1\u201317. https:\/\/doi.org\/10.1126\/scisignal.aat6753","journal-title":"Sci Signal"},{"key":"599_CR103","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"599_CR104","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig 121:1822\u20131826. https:\/\/doi.org\/10.1172\/JCI46110","journal-title":"J Clin Investig"},{"key":"599_CR105","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","volume":"9","author":"A Schmidts","year":"2018","unstructured":"Schmidts A, Maus MV (2018) Making CAR T cells a solid option for solid tumors. Front Immunol 9:2593. https:\/\/doi.org\/10.3389\/fimmu.2018.02593","journal-title":"Front Immunol"},{"key":"599_CR106","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.cir-14-0186","volume":"3","author":"J Scholler","year":"2015","unstructured":"Scholler J, McGettigan SE, Guedan S et al (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 3:356\u2013367. https:\/\/doi.org\/10.1158\/2326-6066.cir-14-0186","journal-title":"Cancer Immunol Res"},{"key":"599_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2018) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980","journal-title":"N Engl J Med"},{"key":"599_CR109","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16:372\u2013385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6","journal-title":"Nat Rev Clin Oncol"},{"key":"599_CR108","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","volume":"132","author":"N Shah","year":"2018","unstructured":"Shah N, Alsina M, Siegel DS et al (2018) Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy. Blood 132:488\u2013488. https:\/\/doi.org\/10.1182\/blood-2018-99-116953","journal-title":"Blood"},{"key":"599_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","volume":"9","author":"NN Shah","year":"2019","unstructured":"Shah NN, Maatman T, Hari P et al (2019) Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol 9:146. https:\/\/doi.org\/10.3389\/fonc.2019.00146","journal-title":"Front Oncol"},{"key":"599_CR111","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"599_CR112","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/bloodadvances.2019000370","volume":"3","author":"S Sidana","year":"2019","unstructured":"Sidana S, Shah N (2019) CAR T-cell therapy: is it prime time in myeloma? Blood Adv 3:3473\u20133480. https:\/\/doi.org\/10.1182\/bloodadvances.2019000370","journal-title":"Blood Adv"},{"issue":"Suppl","key":"599_CR113","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2019.37.15_suppl.7501","volume":"37","author":"T Siddiqi","year":"2019","unstructured":"Siddiqi T, Dorritie KA, Soumerai JD et al (2019) TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymph. J Clin Oncol 37(Suppl):7501. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7501","journal-title":"J Clin Oncol"},{"key":"599_CR114","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3389\/fonc.2020.00885","volume":"10","author":"S Sievers","year":"2020","unstructured":"Sievers S, Watson G, Johncy S et al (2020) Recognizing and grading CAR T-cell toxicities: an advanced practitioner perspective. Front Oncol 10:885. https:\/\/doi.org\/10.3389\/fonc.2020.00885","journal-title":"Front Oncol"},{"key":"599_CR115","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R et al (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105:1684\u20131692. https:\/\/doi.org\/10.1038\/bjc.2011.450","journal-title":"Br J Cancer"},{"key":"599_CR116","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1002\/ajh.25411","volume":"94","author":"SD Smith","year":"2019","unstructured":"Smith SD, Reddy P, Sokolova A et al (2019) Eligibility for CAR T-cell therapy: an analysis of selection criteria and survival outcomes in chemorefractory DLBCL. Am J Hematol 94:E117\u2013E116. https:\/\/doi.org\/10.1002\/ajh.25411","journal-title":"Am J Hematol"},{"key":"599_CR117","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"DG Song","year":"2012","unstructured":"Song DG, Ye Q, Poussin M et al (2012) CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119:696\u2013706. https:\/\/doi.org\/10.1182\/blood-2011-03-344275","journal-title":"Blood"},{"key":"599_CR118","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Sun","year":"2018","unstructured":"Sun J, Leibold J, Cabriolu A et al (2018) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25:82\u201388. https:\/\/doi.org\/10.1038\/s41591-018-0290-5","journal-title":"Nat Med"},{"key":"599_CR119","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","volume":"104","author":"P Tassone","year":"2004","unstructured":"Tassone P, Goldmacher VS, Neri P et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688\u20133696. https:\/\/doi.org\/10.1182\/blood-2004-03-0963","journal-title":"Blood"},{"key":"599_CR120","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"key":"599_CR121","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"599_CR122","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J et al (2008) Adoptive immunotherapy for indolent non-hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112:2261\u20132271. https:\/\/doi.org\/10.1182\/blood-2007-12-128843","journal-title":"Blood"},{"key":"599_CR123","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309.modified","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Riddell SR, Maloney DG et al (2016) CD19 CAR-T cells of defined CD4+\u202f: CD8+ composition in adult B cell ALL patients find the latest version\u202f: CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell all patients. J Clin Investig 126:2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309.modified","journal-title":"J Clin Investig"},{"key":"599_CR124","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA et al (2017) Durable molecular remissions in chronic lymphocytic leukemia treated with cd19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 35:3010\u20133020. https:\/\/doi.org\/10.1200\/JCO.2017.72.8519","journal-title":"J Clin Oncol"},{"key":"599_CR125","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.2147\/DDDT.S138765","volume":"12","author":"S Vairy","year":"2018","unstructured":"Vairy S, Garcia JL, Teira P et al (2018) CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Dev Ther 12:3885\u20133898. https:\/\/doi.org\/10.2147\/DDDT.S138765","journal-title":"Drug Des Dev Ther"},{"key":"599_CR126","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC van der Stegen","year":"2015","unstructured":"van der Stegen SJC, Hamieh M, Sadelain M (2015) The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14:499\u2013509. https:\/\/doi.org\/10.1038\/nrd4597","journal-title":"Nat Rev Drug Discov"},{"key":"599_CR127","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2147\/CMAR.S163225","volume":"11","author":"A Viardot","year":"2019","unstructured":"Viardot A, Wais V, Sala E, Koerper S (2019) Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel. Cancer Manag Res 11:2393\u20132404. https:\/\/doi.org\/10.2147\/CMAR.S163225","journal-title":"Cancer Manag Res"},{"key":"599_CR130","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Han W (2018) Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res 6:4. https:\/\/doi.org\/10.1186\/s40364-018-0116-0","journal-title":"Biomark Res"},{"key":"599_CR129","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015. https:\/\/doi.org\/10.1038\/mto.2016.15","journal-title":"Mol Ther Oncolytics"},{"key":"599_CR128","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1:36. https:\/\/doi.org\/10.1186\/2162-3619-1-36","journal-title":"Exp Hematol Oncol"},{"key":"599_CR131","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2014","unstructured":"Watanabe K, Terakura S, Martens AC et al (2014) Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8 T cells. J Immunol 194:911\u2013920. https:\/\/doi.org\/10.4049\/jimmunol.1402346","journal-title":"J Immunol"},{"key":"599_CR132","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J et al (2008) Retargeting of human t cells to tumor-associated muc1: the evolution of a chimeric antigen receptor. J Immunol 180:4901\u20134909. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4901","journal-title":"J Immunol"},{"key":"599_CR133","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejmc1704610","volume":"377","author":"C Wong","year":"2017","unstructured":"Wong C, Noyes S, Plummer S et al (2017) Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med 377:783\u2013784. https:\/\/doi.org\/10.1056\/nejmc1704610","journal-title":"N Engl J Med"},{"key":"599_CR135","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","volume":"343","author":"XJ Xu","year":"2014","unstructured":"Xu XJ, Tang YM (2014) Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 343:172\u2013178. https:\/\/doi.org\/10.1016\/j.canlet.2013.10.004","journal-title":"Cancer Lett"},{"key":"599_CR134","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.18632\/oncotarget.24179","volume":"9","author":"D Xu","year":"2018","unstructured":"Xu D, Jin G, Chai D et al (2018) The development of CAR design for tumor CAR-T cell therapy. Oncotarget 9:13991\u201314004. https:\/\/doi.org\/10.18632\/oncotarget.24179","journal-title":"Oncotarget"},{"key":"599_CR136","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez L, S\u00e1nchez-Escamilla M, Perales MA (2019) CAR T cell toxicity. HemaSphere 3:e186. https:\/\/doi.org\/10.1097\/HS9.0000000000000186","journal-title":"HemaSphere"},{"key":"599_CR137","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/bst20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku OO, Brentjens RJ (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 44:412\u2013418. https:\/\/doi.org\/10.1042\/bst20150291","journal-title":"Biochem Soc Trans"},{"key":"599_CR138","doi-asserted-by":"publisher","first-page":"33961","DOI":"10.18632\/oncotarget.5582","volume":"6","author":"T Zhang","year":"2015","unstructured":"Zhang T, Cao L, Xie J et al (2015) Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6:33961\u201333971","journal-title":"Oncotarget"},{"key":"599_CR139","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF et al (2017) Engineering CAR-T cells. Biomark Res 5:3\u20138. https:\/\/doi.org\/10.1186\/s40364-017-0102-y","journal-title":"Biomark Res"},{"key":"599_CR140","doi-asserted-by":"publisher","first-page":"1924379","DOI":"10.1155\/2020\/1924379","volume":"2020","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Ping J, Huang Z et al (2020) CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res 2020:1924379. https:\/\/doi.org\/10.1155\/2020\/1924379","journal-title":"J Immunol Res"},{"key":"599_CR142","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao L, Cao YJ (2019) Engineered T cell therapy for cancer in the clinic. Front Immunol 10:2250. https:\/\/doi.org\/10.3389\/fimmu.2019.02250","journal-title":"Front Immunol"},{"key":"599_CR143","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM et al (2018) The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B 8:539\u2013551. https:\/\/doi.org\/10.1016\/j.apsb.2018.03.001","journal-title":"Acta Pharm Sin B"},{"key":"599_CR141","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-019-0705-x","volume":"12","author":"J Zhao","year":"2019","unstructured":"Zhao J, Song Y, Liu D (2019) Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol 12:17. https:\/\/doi.org\/10.1186\/s13045-019-0705-x","journal-title":"J Hematol Oncol"},{"key":"599_CR144","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.12602","volume":"96","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Tan Y, Ou R et al (2016) Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol 96:389\u2013396. https:\/\/doi.org\/10.1111\/ejh.12602","journal-title":"Eur J Haematol"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-020-00599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00005-020-00599-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-020-00599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T15:49:29Z","timestamp":1704210569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00005-020-00599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s00005-020-00599-x","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"34"}}